Suppr超能文献

一种铁载体头孢菌素S-649266对肠杆菌科临床分离株(包括耐碳青霉烯菌株)的体外抗菌活性

In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains.

作者信息

Kohira Naoki, West Joshua, Ito Akinobu, Ito-Horiyama Tsukasa, Nakamura Rio, Sato Takafumi, Rittenhouse Stephen, Tsuji Masakatsu, Yamano Yoshinori

机构信息

Discovery Research Laboratory for Core Therapeutic Areas, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan

GlaxoSmithKline, Collegeville, Pennsylvania, USA.

出版信息

Antimicrob Agents Chemother. 2015 Nov 16;60(2):729-34. doi: 10.1128/AAC.01695-15. Print 2016 Feb.

Abstract

S-649266 is a novel siderophore cephalosporin antibiotic with a catechol moiety on the 3-position side chain. Two sets of clinical isolate collections were used to evaluate the antimicrobial activity of S-649266 against Enterobacteriaceae. These sets included 617 global isolates collected between 2009 and 2011 and 233 β-lactamase-identified isolates, including 47 KPC-, 49 NDM-, 12 VIM-, and 8 IMP-producers. The MIC90 values of S-649266 against the first set of Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, Citrobacter freundii, Enterobacter aerogenes, and Enterobacter cloacae isolates were all ≤1 μg/ml, and there were only 8 isolates (1.3%) among these 617 clinical isolates with MIC values of ≥8 μg/ml. In the second set, the MIC values of S-649266 were ≤4 μg/ml against 109 strains among 116 KPC-producing and class B (metallo) carbapenemase-producing strains. In addition, S-649266 showed MIC values of ≤2 μg/ml against each of the 13 strains that produced other types of carbapenemases such as SME, NMC, and OXA-48. The mechanisms of the decreased susceptibility of 7 class B carbapenemase-producing strains with MIC values of ≥16 μg/ml are uncertain. This is the first report to demonstrate that S-649266, a novel siderophore cephalosporin, has significant antimicrobial activity against Enterobacteriaceae, including strains that produce carbapenemases such as KPC and NDM-1.

摘要

S-649266是一种新型的铁载体头孢菌素抗生素,其3位侧链带有儿茶酚部分。使用两组临床分离株集合来评估S-649266对肠杆菌科细菌的抗菌活性。这些集合包括2009年至2011年收集的617株全球分离株以及233株经β-内酰胺酶鉴定的分离株,其中包括47株产KPC酶、49株产NDM酶、12株产VIM酶和8株产IMP酶的菌株。S-649266对第一组大肠杆菌、肺炎克雷伯菌、粘质沙雷氏菌、弗氏柠檬酸杆菌、产气肠杆菌和阴沟肠杆菌分离株的MIC90值均≤1μg/ml,在这617株临床分离株中,只有8株(1.3%)的MIC值≥8μg/ml。在第二组中,S-649266对116株产KPC酶和产B类(金属)碳青霉烯酶的菌株中的109株的MIC值≤4μg/ml。此外,S-649266对13株产其他类型碳青霉烯酶(如SME、NMC和OXA-48)的菌株的MIC值均≤2μg/ml。7株MIC值≥16μg/ml的产B类碳青霉烯酶菌株敏感性降低的机制尚不清楚。这是首次报道表明新型铁载体头孢菌素S-649266对肠杆菌科细菌具有显著的抗菌活性,包括产碳青霉烯酶(如KPC和NDM-1)的菌株。

相似文献

8
Genomic Modification of TonB and Emergence of Small-Colony Phenotype in VIM- and NDM-Producing Escherichia coli following Cefiderocol Exposure .
Antimicrob Agents Chemother. 2023 May 17;67(5):e0011823. doi: 10.1128/aac.00118-23. Epub 2023 Apr 6.

引用本文的文献

2
Structural Insights into Cir-mediated Killing by the Antimicrobial Protein Microcin V.
bioRxiv. 2025 Mar 9:2025.03.06.641670. doi: 10.1101/2025.03.06.641670.
6
Real-Life Cefiderocol Use in Bone and Joint Infection: A French National Cohort.
Antibiotics (Basel). 2025 Apr 8;14(4):388. doi: 10.3390/antibiotics14040388.
9
Carbapenem-resistant infections after liver transplantation: Drug resistance, risk factors and impact on prognosis.
World J Gastroenterol. 2025 Feb 28;31(8):98415. doi: 10.3748/wjg.v31.i8.98415.
10
Difficult-to-Treat Infections in Critically Ill Patients: A Comprehensive Review and Treatment Proposal.
Antibiotics (Basel). 2025 Feb 11;14(2):178. doi: 10.3390/antibiotics14020178.

本文引用的文献

1
Stability of Novel Siderophore Cephalosporin S-649266 against Clinically Relevant Carbapenemases.
Antimicrob Agents Chemother. 2016 Jun 20;60(7):4384-6. doi: 10.1128/AAC.03098-15. Print 2016 Jul.
2
Transferrin-mediated iron sequestration as a novel therapy for bacterial and fungal infections.
Curr Opin Microbiol. 2015 Oct;27:57-61. doi: 10.1016/j.mib.2015.07.005. Epub 2015 Aug 9.
3
Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010-2013).
Diagn Microbiol Infect Dis. 2015 Oct;83(2):183-6. doi: 10.1016/j.diagmicrobio.2015.06.011. Epub 2015 Jun 23.
4
In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.
Antimicrob Agents Chemother. 2015 Jul;59(7):4239-48. doi: 10.1128/AAC.00206-15. Epub 2015 May 11.
6
Antimicrobial consumption and resistance in five Gram-negative bacterial species in a hospital from 2003 to 2011.
J Microbiol Immunol Infect. 2015 Dec;48(6):647-54. doi: 10.1016/j.jmii.2014.04.009. Epub 2014 May 23.
8
Antibiotics in the clinical pipeline in 2013.
J Antibiot (Tokyo). 2013 Oct;66(10):571-91. doi: 10.1038/ja.2013.86. Epub 2013 Sep 4.
9
Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013.
Euro Surveill. 2013 Jul 11;18(28):20525. doi: 10.2807/1560-7917.es2013.18.28.20525.
10
Clinically relevant Gram-negative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbam.
Antimicrob Agents Chemother. 2012 Dec;56(12):6334-42. doi: 10.1128/AAC.01345-12. Epub 2012 Oct 1.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验